Grafa News and Videos — Page 1092

Cosmos Health (NASDAQ:COSM), a diversified global healthcare group, has announced record-breaking financial results for the fiscal year ended December 31, 2025.

USA Rare Earth (NASDAQ:USAR) announced a major operational milestone on April 15, 2026, with the first commercial pour of yttrium metal at its subsidiary, Less Common Metals (LCM), located in Cheshire, UK.

Nixxy (NASDAQ:NIXX) has reported its financial results for fiscal year 2025, marking the successful conclusion of a multi-year strategic transformation.

Canaan (NASDAQ:CAN), a leading provider of high-performance computing solutions and a pioneer in Bitcoin mining hardware, has released its unaudited operational update for March 2026.

XTI Aerospace (NASDAQ:XTIA) has released its financial results for the full year 2025 and provided an optimistic outlook for 2026, marking its first comprehensive reporting period since the $40 million acquisition of Drone Nerds in late 2025.

Stereotaxis (NYSE:STXS), a pioneer in innovative robotic technologies for the treatment of arrhythmias and endovascular disease, announced today that it has entered into a definitive agreement to acquire Robocath.

Viant Technology (NASDAQ:DSP), a prominent player in AI-powered programmatic advertising, announced today that it has entered into a definitive agreement to acquire TVision Insights.

Raytheon, an RTX (NYSE:RTX) business, achieved a major milestone in its next-generation sensing portfolio on April 15, 2026, with the successful completion of the first flight test of the RAIVEN Staring sensing system.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) announced on April 15, 2026, a strategic partnership with Runway Health to make ARAKODA (tafenoquine) available to U.S. travelers via a dedicated telehealth platform.

Immutep (NASDAQ:IMMP), a clinical-stage biotechnology company developing LAG-3 immunotherapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead product candidate, eftilagimod alfa (efti), for the treatment of soft tissue sarcoma (STS).